Search
for
Sort by
Research 61–90 of 1000+
- withdrawn
- Associations between semen quality and lower urinary tract symptoms in ageing male
- MP89-08 POST-FINASTERIDE SYNDROME: REAL OR IMAGINED?
- Pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome
- (719) Signal Detection of Depression and Suicidality With the 5-Alpha Reductase Inhibitors: Evidence from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) Database
- Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial
- Efficacy and Side Effects of Drugs Commonly Used for the Treatment of Lower Urinary Tract Symptoms Associated With Benign Prostatic Hyperplasia
- Efficacy and safety of 5 alpha-reductase inhibitor monotherapy in patients with benign prostatic hyperplasia: A meta-analysis
- Efficacy and safety of Finasteride (5 alpha-reductase inhibitor) monotherapy in patients with benign prostatic hyperplasia: A critical review of the literature
- Cross‐Sex Hormone Therapy in Trans Persons Is Safe and Effective at Short‐Time Follow‐Up: Results from the European Network for the Investigation of Gender Incongruence
- Dutasteride
- Efficacy and safety of oral finasteride <i>versus</i> dutasteride in moderate-to-severe androgenetic alopecia in males based on trichoscopic and laboratory findings: a clinical comparison in Iran
- Mesotherapy With Dutasteride for Androgenetic Alopecia: A Retrospective Study in Real Clinical Practice.
- Safety, tolerability, and pharmacokinetics of CG2001 in Chinese adult male subjects with androgenetic alopecia: a randomized, double-blind, placebo-controlled, single- and multi-doses, phase 1 clinical study
- Safety Analysis of Panax Ginseng in Randomized Clinical Trials: A Systematic Review
- Repurposing steroidogenesis inhibitors for the therapy of neuropsychiatric disorders: Promises and caveats
- Serenoa repens induced erectile dysfunction: Underdiagnosis and phytovigilance
- Microneedling plus topical dutasteride solution for androgenetic alopecia: a randomized placebo‐controlled study
- Safety and efficacy of advanced and targeted acid α-glucosidase (AT-GAA) (ATB200/AT2221) in ERT-switch nonambulatory patients with Pompe disease: preliminary results from the ATB200-02 trial
- PD49-03 IS TADALAFIL ASSOCIATED WITH DECREASED RISK OF MAJOR ADVERSE CARDIAC EVENTS OR VENOUS THROMBOEMBOLISM IN MEN WITH LOWER URINARY TRACT SYMPTOMS?
- Sexual Adverse Effects of Finasterid 1mg for Treatment of Androgenic Alopecia in Men
- Neuropsychiatric Adverse Events of Montelukast: An Analysis of Real-World Datasets and drug−gene Interaction Network
- Drug-associated insomnia: A pharmacovigilance study based on FDA adverse event reporting system
- Suicidality Risks Associated with Finasteride, a 5-Alpha Reductase Inhibitor: An Evaluation of Real-World Data from the FDA Adverse Event Reports
- Adverse Side Effects of 5α‐Reductase Inhibitors Therapy: Persistent Diminished Libido and Erectile Dysfunction and Depression in a Subset of Patients
- Faculty Opinions recommendation of Adverse Event Reporting in Clinical Trials of Finasteride for Androgenic Alopecia: A Meta-analysis.
- Adverse events of the thyroid peroxidase inhibitor methimazole in the treatment of hyperthyroidism: a comprehensive analysis from the first quarter of 2004 to the first quarter of 2025
- Sexual, physical, and overall adverse effects in patients treated with 5α-reductase inhibitors: a systematic review and meta-analysis
- Evaluating the safety profile of α-1 blockers, 5α-reductase inhibitors, and PDE5I for BPH: a disproportionality analysis of real-world adverse events based on FDA adverse event reporting system (FAERS)
- Signal Detection for Adverse Events of Finasteride Using Korea Adverse Event Reporting System (KAERS) Database